In practice, systemic-first strategies are reasonable for asymptomatic, small-volume brain metastases from EGFR/ALK-driven NSCLC or BRAF-mutant melanoma, initiating CNS-active systemic therapy and deferring focal radiotherapy with MRI surveillance every 6–8 weeks. The gene discussed is ALK; the disease is melanoma.